September 6, 2017 - The court ordered the authorization of the distribution of the net settlement fund.
August 23, 2016 - The court ordered the authorization of the distribution of the net settlement fund.

July 23, 2015 - The court approved the settlement.

June 11, 2015 - The court held a final settlement hearing.

January 16, 2015 - The court preliminarily approved the settlement.

November 26, 2014 - Parties filed a stipulation of settlement.

April 18, 2014 - The court denied the defendants' motion to dismiss.

September 13, 2013 - The lead plaintiff filed a consolidated complaint.

July 19, 2013 - The court ordered a plaintiff is voluntarily dismissed.

July 16, 2013 - A plaintiff filed a notice of voluntary dismissal without prejudice.

July 2, 2013 - The lead plaintiff and lead counsel were appointed and all cases were consolidated.

May 6, 2013 - Lead plaintiff motions were filed.

April 8, 2013 - Another investor filed a complaint in the U.S. District Court for the Northern District of California on behalf of investors who purchased Impax Laboratories Inc (NASDAQ: IPXL) common shares between February 25, 2011 and March 4, 2013.

March 7, 2013 - An investor in shares of Impax Laboratories Inc (NASDAQ: IPXL) filed a lawsuit in the U.S. District Court for the Northern District of California against Impax Laboratories Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between June 6, 2011 and March 4, 2013 in regards to the Hayward facility.

According to the complaint the plaintiff alleges on behalf of purchasers of Impax Laboratories Inc (NASDAQ: IPXL) common stock during the period between June 6, 2011 and March 4, 2013, that Impax Laboratories Inc and certain of its officers and directors violated the Securities Exchange Act of 1934.

Between June 6, 2011 and March 4, 2013 Impax Laboratories Inc received a warning letter from the U.S. Food and Drug Administration ( FDA ), dated May 31, 2011, related to an inspection of its Hayward, California facility, which cited problems in deviation from current good manufacturing practices.

The plaintiff claims that the defendants allegedly issued false and misleading statements to the investing public in connection with their efforts to correct manufacturing deficiencies at Impax Laboratories Inc's Hayward facility, and the impact the deficiencies would have on Impax Laboratories Inc's ability to gain FDA approval for RYTARY(TM), an extended-release drug for treatment of Parkinson's disease.

On March 4, 2013, Impax Laboratories Inc announced that the FDA completed its re-inspection of Impax Laboratories Inc’s Hayward manufacturing facility in connection with the previously disclosed Form 483 issued in March 2012. Impax Laboratories Inc said that at the conclusion of this inspection, the FDA issued a new Form 483 with twelve (12) observations, three (3) of which are designated as repeat observations from inspections that occurred prior to the warning letter.

Shares of Impax Laboratories Inc (NASDAQ: IPXL) dropped from $20.00 on March 4, 2013, to as low as $14.49 per share on March 5, 2013.

The plaintiff alleges that as a result of defendants' statements between June 6, 2011 and March 4, 2013, Impax Laboratories Inc’s (NASDAQ: IPXL) stock traded at artificially inflated prices, reaching a high of $27.02 per share on October 2, 2012.

The plaintiff seeks to recover damages on behalf of all purchasers of Impax Laboratories Inc (NASDAQ: IPXL) common stock between June 6, 2011 and March 4, 2013.

On March 7, 2013, Impax Laboratories Inc (NASDAQ: IPLX) shares closed at $16.00 per share.